[
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-1",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#definitiongeneral396276",
    "clean_content": "Definition / general\n\n* Low, intermediate or high grade subset of neuroendocrine tumors (NET) that lack necrosis and express neuroendocrine markers (synaptophysin or chromogranin A)"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-2",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#essentialfeatures396277",
    "clean_content": "Essential features\n\n* WHO Classification of Tumours of Endocrine Organs (2017) and WHO Classification of Tumours of the Digestive System (2019) classifies well differentiated pancreatic neuroendocrine tumors (PanNETs) as grade 1, grade 2 or grade 3 (see [Diagnosis](https://www.pathologyoutlines.com/topic/pancreasWDNET.html#RBpancreasWDNETdiagnosis))* Classification uses criteria similar to other gastrointestinal neuroendocrine neoplasms* May be nonfunctioning or secrete 1 or more peptides; multiple tumors in the same patient may secrete the same or different peptides"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-3",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#terminology396278",
    "clean_content": "Terminology\n\n* Synonyms: well differentiated neuroendocrine tumor (WD NET), pancreatic neuroendocrine tumor (PanNET), pancreatic endocrine tumor, islet\n  cell tumor* Specific functional terms (glucagonoma, insulinoma, gastrinoma) not\n    recommended for use unless hormonal syndrome exists clinically* Microscopic lesions < 0.5 cm are termed microadenomas* Carcinoid is a term that should be avoided if possible"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-4",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#icdcoding396279",
    "clean_content": "ICD coding\n\n* ICD-10: [C25](https://www.icd10data.com/ICD10CM/Codes/C00-D49/C15-C26/C25-/C25) - malignant neoplasm of pancreas"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-5",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#epidemiology396280",
    "clean_content": "Epidemiology\n\n* M = F* Peak incidence: 30 - 60 years* Comprise ~2 - 5% of pancreatic neoplasms ([J Gastrointest Surg 2010;14:541](19997980))* Most are sporadic; risk factors include ([Ann Oncol 2016;27:68](26487581)):\n        + Family history of cancer (not site dependent; lung, colon, among others)+ Elevated BMI+ Diabetes+ Cigarette smoking+ Elevated alcohol consumption* 10 - 20% are associated with syndromes:\n          + Multiple endocrine neoplasia type 1 (MEN1): nearly 100% pancreatic involvement at autopsy ([Surgery 1979;86:475](38521))+ Von Hippel-Lindau (VHL): 12.3 - 17% of patients ([Surgery 2007;142:814](18063061), [Gastroenterology 2000;119:1087](11040195))+ Neurofibromatosis type 1: 10% of patients ([Crit Rev Oncol Hematol 2022;172:103648](35248713))+ Tuberous sclerosis: 1 - 9% of patients ([Crit Rev Oncol Hematol 2022;172:103648](35248713))* Nonfunctional tumors represent 60 - 90% of all PanNETs ([Neuroendocrinology 2016;103:153](26742109), [Biomed Res Int 2017;2017:9856140](29349087))* Functional tumors (10 - 40%):\n              + Insulinoma (most common, account for 4 - 20% of PanNETs) ([J Gastroenterol 2015;50:58](24499825))+ Gastrinoma (second most common, account for 4 - 8% of PanNETs) ([J Gastroenterol 2015;50:58](24499825))+ VIPoma (< 2% of PanNETs) ([Endocr J 2022;69:1201](35644576))+ Glucagnoma (1 - 2% of PanNETs) ([Ann Surg Oncol 2007;14:3492](17896148))+ Somatostatinoma (< 1% of PanNETs) ([J Gastroenterol Hepatol 2008;23:521](17645474))+ ACTH producing neuroendocrine tumor (< 1% of PanNETs) ([Am J Surg Pathol 2015;39:374](25353285))+ Serotonin producing neuroendocrine tumor (up to 3.9%) ([Am J Surg Pathol 2015;39:592](25602797))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-6",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#sites396281",
    "clean_content": "Sites\n\n* Found throughout the pancreas* Nonfunctional, gastrinomas or serotonin producing tumors are more likely to be found in the head of the pancreas* Insulinomas, glucagonomas and VIPomas are more likely to be found in the tail ([Ann Surg Oncol 2007;14:3492](17896148))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-7",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#pathophysiology396282",
    "clean_content": "Pathophysiology\n\n* Theorized to arise from totipotent stem cells in the pancreatic ductal system and islets of Langerhans ([Endotext: Pathophysiology and Treatment of Pancreatic Neuroendocrine Tumors [Accessed 30 September 2022]](25905300))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-8",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#etiology396283",
    "clean_content": "Etiology\n\n* Majority are sporadic and nonsyndromic* Minority are associated with multiple endocrine neoplasia syndrome (80 - 100% incidence), tuberous sclerosis (rare), von Hippel-Lindau (VHL, 10 - 17% incidence), among others ([Cancer 2008;113:1807](18798544))* Hyperplastic and preneoplastic lesions were removed from the WHO 2017; PanNEN precursor lesions have not been clearly associated with sporadic neoplasms (but are described in MEN1 and VHL)"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-9",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#clinicalfeatures396284",
    "clean_content": "Clinical features\n\n* Demonstrate a spectrum of clinical behavior dependent on hormones\n  produced* Commonly causes abdominal pain, jaundice* Asymptomatic pancreatic neuroendocrine tumors are increasingly common, likely because of an increase in detection due to increased imaging frequency and improvement in imaging modalities ([Cancer 2015;121:589](25312765))* Functional tumors may have elevated serum peptides corresponding to tumor cell type* May be associated with carcinoid syndrome (flushing, diarrhea) if metastatic to liver* Most nonfunctional tumors are large and detected at an advanced stage at diagnosis, with 60 - 85% having liver metastases ([Cancer 2008;113:1807](18798544))* Liver is the most common site of metastasis* Insulinoma:\n                + Composed of insulin producing cells with uncontrolled secretion of insulin+ Clinical: Whipple triad (hypoglycemic symptoms, plasma glucose < 40 mg/dL and symptom relief after glucose administration)+ Typically, small (< 2 cm diameter) and solitary (~10% multiple, usually in MEN1 patients) ([Neoplasma 2015;62:484](25866230))* Gastrinoma:\n                  + Composed of gastrin producing cells with uncontrolled secretion of gastrin+ Clinical: Zollinger-Ellison syndrome (reflux symptoms and duodenal ulcers)+ Typically, large size (average 3.8 cm diameter), more common in the duodenum than in the pancreas ([Wien Klin Wochenschr 2007;119:579](17985091))* VIPoma:\n                    + Composed of uncontrolled vasoactive intestinal peptide (VIP) secreting cells+ Clinical: WDHA syndrome (watery diarrhea [persists when fasting], hypokalemia and achlorhydria)+ Typically, large (average ~5 cm diameter) and solitary ([Ann N Y Acad Sci 1988;527:508](2839087))* Glucagonoma:\n                      + Composed of cells with uncontrolled secretion of glucagon and preglucagon derived peptide+ Clinical: triad of skin rash (necrolytic migratory erythema), diabetes mellitus and weight loss+ Typically, variable in size (average 3 - 7 cm diameter) and solitary ([Medicine (Baltimore) 1996;75:53](8606627))* Somatostatinoma:\n                        + Composed of cells that demonstrate D cell differentiation with uncontrolled secretion of somatostatin+ Clinical: less distinctive than other functioning PanNETs (glucose intolerance, cholelithiasis and diarrhea)+ Typically, large (average 5 - 6 cm diameter) and multinodular ([J Exp Clin Cancer Res 1999;18:13](10374671))* ACTH producing neuroendocrine tumor:\n                          + Composed of cells secreting uncontrolled adrenocorticotropic hormone (ACTH)\n                            - Clinical: features of Cushing syndrome (central obesity, weight gain, moon face, hypertension, hyperglycemia, osteoporosis, hypokalemia and cutaneous hyperpigmentation)+ Typically, large (average 4.8 cm diameter) and solitary ([Am J Surg Pathol 2015;39:374](25353285))* Serotonin producing neuroendocrine tumor:\n                            + Composed of cells secreting uncontrolled serotonin+ Clinical (usually only after metastasizing to the liver): carcinoid syndrome (abdominal pain, flushing, diarrhea and weight loss)+ Typically large (average ~5 cm diameter) and solitary ([Pancreas 2011;40:883](21705949))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-10",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#diagnosis396285",
    "clean_content": "Diagnosis\n\n+ Requires neuroendocrine histology and positive staining for neuroendocrine and cytokeratin makers (and the presence of clinical symptoms if functional)+ Contains < 30% of the neoplasm volume of a second tumor type (ductal, acinar etc.) (otherwise, see [mixed neuroendocrine nonneuroendocrine neoplasms [MiNEN]](https://www.pathologyoutlines.com/topic/pancreasmixed.html))+ Does not contain necrosis or severe atypia (otherwise, see [neuroendocrine carcinoma [PanNEC]](https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html))+ Well differentiated tumors are classified by mitotic count and proliferative index (Ki67):\n        - G1 (NET G1): mitotic count < 2/2 mm2 and < 3% Ki67 index- G2 (NET G2): mitotic count 2 - 20/2 mm2 or 3 - 20% Ki67 index- G3 (NET G3): mitoses > 20/2 mm2 or > 20% Ki67 index"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-11",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#laboratory396286",
    "clean_content": "Laboratory\n\n* Elevated serum chromogranin A levels (> 15 ng/mL) show a sensitivity of 66% and a specificity of 95% for the diagnosis pancreatic neuroendocrine tumors ([World J Gastroenterol 2020;26:2305](32476795))* Elevated serum neuron specific enolase (NSE) and pancreatic polypeptide (PP) are respectively seen in up to 30 - 50% and 50% of PNET patients ([Front Oncol 2020;10:831](32537434))* Specific biomarkers for functional PNET are not currently recommended due to their poor sensitivity, specificity and lack of standardization between laboratories ([Surg Oncol Clin N Am 2020;29:165](32151354))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-12",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#radiologydescription396287",
    "clean_content": "Radiology description\n\n* General: highly vascular, well circumscribed enhancing lesion that can be solid or cystic* Ultrasound: circumscribed masses with smooth margins, suboptimal visualization of the body and tail due to bowel gas obstruction, sensitivity of 20 - 80%* CT: well defined, uniformly hypervascular masses on arterial phase CT, most widely available technique* MRI: hyperintense on T1 weighted imaging due to an abundance of proteinaceous material and variable signal on T2 weighted images; better resolution than CT ([Semin Ultrasound CT MR 2019;40:469](31806146))* 68Ga SRS (stimulated Raman scattering) is a type of PET imaging of somatostatin receptor, current gold standard for functional imaging of NETs ([Nat Rev Endocrinol 2018;14:656](30158549))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-13",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#radiologyimages396288",
    "clean_content": "Radiology images\n\nImages hosted on other servers:  \n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasWDNETradio1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701459/figure/f1-amjcaserep-18-1220/)\n\nLarge mass in pancreas tail"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-14",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#prognosticfactors396289",
    "clean_content": "Prognostic factors\n\n* Relatively indolent but with variable outcome* Features associated with adverse outcome ([Am J Surg Pathol 2007;31:1677](18059224), [HPB (Oxford) 2009;11:422](19768147), [Sci Rep 2018;8:7271](29739948)):\n    + Size > 2 cm+ Tumor necrosis+ Lymph node positivity+ Mitoses > 2/10 high powered fields+ Vascular invasion+ Perineural invasion+ High Ki67 index+ CK19 positivity+ Loss of *DAXX* / *ATRX* expression and alternative lengthening of telomeres suggest poor outcome ([Clin Cancer Res 2017;23:600](27407094), [Front Endocrinol (Lausanne) 2021;12:691557](34220718))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-15",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#casereports396290",
    "clean_content": "Case reports\n\n* 23 year old woman with *VHL* and *SDHA* pathogenic variant co-occurrence in PanNET ([Front Oncol 2022;12:925582](35875079))* 43 year old man with MEN1 and metastatic grade 3 PanNET ([J Endocr Soc 2022;6:bvac122](36111275))* 44 year old woman with recurrent pancreatic glucagonoma ([Ann Med Surg (Lond) 2022;77:103604](35638031))* 62 year old man with metastases ([J Med Life 2018;11:57](29696066))* 69 year old man with pancreatic insulinoma presenting with postprandial hypoglycemia ([AACE Clin Case Rep 2022;8:154](35959085))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-16",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#treatment396291",
    "clean_content": "Treatment\n\n* Primarily surgical (benefits shown for primary and metastatic disease)* Enucleation can be used for small and localized tumors* First line treatments for metastatic disease are somatostatin analogs (octreotide and lanreotide)* Second line treatments include tyrosine kinase inhibitors (sunitinib) and mTOR inhibitors (everolimus)* Novel chemotherapy regime of capeciabine and temozolomide (CAPTEM) and peptide receptor radionuclide therapy (PRRT) has been approved* Reference: [Surg Clin North Am 2019;99:793](31255207)"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-17",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#grossdescription396292",
    "clean_content": "Gross description\n\n* Solid, well circumscribed mass, typically 2 - 5 cm in diameter* Larger tumors often show heterogenous and lobulated cut surfaces* Color can range from red-tan to brown-yellow* May show extensive fibrosis, calcification or ossification* 5% are cystic (unilocular, less commonly multilocular) but necrosis is uncommon in well differentiated PanNETs* Reference: [Arch Pathol Lab Med 2019;143:1317](31509453)"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-18",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#grossimages396293",
    "clean_content": "Gross images\n\n*Contributed by Katrina Krogh, M.D.*  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough01.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough01.jpg)\n\nWell circumscribed mass\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough02.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough02.jpg)\n\nCut surface of mass\n\n  \n  \nImages hosted on other servers:  \n\n[![](https://www.pathologyoutlines.com/thumb/pancreasWDNETcdn01.jpg)](https://image.slidesharecdn.com/lestumeurscarcinodesfinal-170212190140/95/les-tumeurs-carcinodes-final-13-638.jpg)\n\nInvasion of large vessel\n\n[![](https://www.pathologyoutlines.com/thumb/pancreasWDNETgrossncbi1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC368446/figure/F2/)\n\nTumor in isthmus / body"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-19",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#microscopichistologicdescription396294",
    "clean_content": "Microscopic (histologic) description\n\n* Architecture can be solid, organoid, nesting, gyriform, trabecular or glandular* Small, round monotonous cells with coarse, salt and pepper nuclear chromatin and minimal atypia* Occasional small nucleoli are most common; large nucleoli can be seen* Cytoplasm can be pale pink, oncocytic, granular or lipid rich / vacuolated* Rarely, nuclei can be eccentrically located (rhabdoid cell appearance) ([Am J Surg Pathol 2003;27:642](12717248))* Islet amyloid polypeptide (amylin) deposition is specific for insulinoma but is only seen in ~5% of cases* Psammoma bodies can be seen in somatostatinomas"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-20",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#microscopichistologicimages396295",
    "clean_content": "Microscopic (histologic) images\n\n*Contributed by Katrina Krogh, M.D.*  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough23new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough23new.jpg)\n\nTrabecular growth\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough24new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough24new.jpg)\n\nNeuroendocrine nuclei\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough04new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough04new.jpg)\n\nPanNET (VIPoma) metastatic to liver\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough19new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough19new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough05new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough05new.jpg)\n\nKi67\n\n  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough21new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough21new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough22new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough22new.jpg)\n\nSynaptophysin\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough03new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough03new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough17new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough17new.jpg)\n\nChromogranin\n\n  \n  \nContributed by [@RaulSGonzalezMD](https://twitter.com/RaulSGonzalezMD) on Twitter  \n\n[![Well differentiated neuroendocrine tumor](https://www.pathologyoutlines.com/imgau/pancreasWDNETRaulSGonzalezMD01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasWDNETRaulSGonzalezMD01.jpg)\n \n[![Well differentiated neuroendocrine tumor](https://www.pathologyoutlines.com/imgau/pancreasWDNETRaulSGonzalezMD02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasWDNETRaulSGonzalezMD02.jpg)\n \n[![Well differentiated neuroendocrine tumor](https://www.pathologyoutlines.com/imgau/pancreasWDNETRaulSGonzalezMD03.jpg)](https://www.pathologyoutlines.com/imgau/pancreasWDNETRaulSGonzalezMD03.jpg)\n\nWell differentiated neuroendocrine tumor"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-21",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#cytologydescription396296",
    "clean_content": "Cytology description\n\n* Single cell type; monotonous plasmacytoid cells with moderate amount of cytoplasm and distinctive neuroendocrine chromatin ([Clin Cancer Res 2017;23:600](27407094))* Can have rosette-like aggregates and eccentric nuclei"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-22",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#cytologyimages396297",
    "clean_content": "Cytology images\n\n*Contributed by Katrina Krogh, M.D.*  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough18new.jpg)](https://www.pathologyoutlines.com/imgau/pancreascarcinoidKrough18new.jpg)\n\nDiff-Quik"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-23",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#positivestains396298",
    "clean_content": "Positive stains\n\n* [Chromogranin A](https://www.pathologyoutlines.com/topic/stainschromogranin.html) (more specific) and [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) (more sensitive):\n  diffuse and strong* [NSE](https://www.pathologyoutlines.com/topic/stainsNSE.html), [CD56](https://www.pathologyoutlines.com/topic/cdmarkerscd56.html), [CD57](https://www.pathologyoutlines.com/topic/cdmarkerscd57.html)* [AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html), [CAM5.2](https://www.pathologyoutlines.com/topic/stainscam52.html) and [CK8/18](https://www.pathologyoutlines.com/topic/CK818.html)* [Somatostatin](https://www.pathologyoutlines.com/topic/stainssomatostatin.html) receptor is positive in 80 - 90% and [PR](https://www.pathologyoutlines.com/topic/stainsprog.html) is positive in 58% of PanNETs ([Hum Pathol 2020;96:8](31857137))* Immunohistochemistry for peptide hormones (insulin, glucagon, VIP, etc.) is rarely required and nonfunctional tumors may be positive* [SMAD4](https://www.pathologyoutlines.com/topic/stainsdpc4.html) and [Rb](https://www.pathologyoutlines.com/topic/stainsrb.html) retained\n            + In metastatic setting: [Isl1](https://www.pathologyoutlines.com/topic/stainsislet1.html) (most sensitive) and **PAX6** positivity is supportive+ [PAX8](https://www.pathologyoutlines.com/topic/stainspax8.html) (polyclonal) is positive in 50 - 60% of cases metastatic to the liver (monoclonal [PAX8](https://www.pathologyoutlines.com/topic/stainspax8.html) is negative) ([Hum Pathol 2020;96:8](31857137))* **NESP55**+ and **PDX1**+, in the presence of negative [CDX2](https://www.pathologyoutlines.com/topic/stainscdx2.html) and\n              [TTF1](https://www.pathologyoutlines.com/topic/stainsttf1.html), is 97% specific for pancreatic origin ([Clin Cancer Res 2017;23:600](27407094))"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-24",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#negativestains396299",
    "clean_content": "Negative stains\n\n* [CDX2](https://www.pathologyoutlines.com/topic/stainscdx2.html), [SATB2](https://www.pathologyoutlines.com/topic/stainssatb2.html) and [TTF1](https://www.pathologyoutlines.com/topic/stainsttf1.html) ([Surg Oncol Clin N Am 2020;29:185](32151355))* Nuclear [beta catenin](https://www.pathologyoutlines.com/topic/stainsbetacatenin.html)* [Trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html) / [chymotrypsin](https://www.pathologyoutlines.com/topic/stainsalpha1antichymo.html)* [BCL10](https://www.pathologyoutlines.com/topic/stainsbcl10.html)* [SMA](https://www.pathologyoutlines.com/topic/stainsalphasmoothmuscleactin.html)"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-25",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#molecularcytogeneticsdescription396300",
    "clean_content": "Molecular / cytogenetics description\n\n* Frequently mutated genes ([Science 2011;331:1199](21252315), [Endocr Relat Cancer 2009;16:1219](19690016), [Expert Rev Gastroenterol Hepatol 2015;9:1407](26413978)):\n  + *MEN1* (44.1%)+ *DAXX* (death domain associated protein, 25%)+ *ATDX* ([alpha] thalassemia / intellectual disability syndrome X linked,\n        17.6%)+ *TSC2* (8.8%)+ *PTEN* (7.3%)+ *PI3KCA* (1%)+ *VHL* (up to 25% including deletion by promoter methylation)"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-26",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Molecular / cytogenetics images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#molecularcytogeneticsimages396301",
    "clean_content": "Molecular / cytogenetics images\n\nImages hosted on other servers:  \n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasWDNETmol1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971513/figure/fig3-0300060517728653/)\n\n*MEN1* mutation"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-27",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#samplepathologyreport396302",
    "clean_content": "Sample pathology report\n\n* Distal pancreas and spleen, distal pancreatectomy and splenectomy:\n  + Well differentiated neuroendocrine tumor, WHO grade 2, measuring 4.1 cm in greatest dimension (see comment)+ Lymphovascular and perineural invasion identified+ Pancreatic resection margin, negative for tumor+ 2 of 10 lymph nodes, positive for metastatic tumor (2/10)+ Spleen with no significant pathologic change+ Pathologic stage: pT3, pN1+ Comment: Immunohistochemical stains are performed and show the tumor cells are positive for cytokeratin AE1 / AE3, synaptophysin and chromogranin (patchy). The Ki67 proliferative index is 15%. Beta catenin shows membranous staining (negative result). Overall findings are consistent with 2019 WHO grade 2 (out of 3)."
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-28",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#differentialdiagnosis396303",
    "clean_content": "Differential diagnosis\n\n* [Solid pseudopapillary neoplasm](https://www.pathologyoutlines.com/topic/pancreassolidpseudo.html):\n  + Positive stains: nuclear [beta catenin](https://www.pathologyoutlines.com/topic/stainsbetacatenin.html), cytoplasmic / perinuclear [CD10](https://www.pathologyoutlines.com/topic/cdmarkerscd10.html), nuclear [PR](https://www.pathologyoutlines.com/topic/stainsprog.html), [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) (sometimes), [pankeratins](https://www.pathologyoutlines.com/topic/stainsae1ae3.html) (variable)+ Negative stains: membranous [E-cadherin](https://www.pathologyoutlines.com/topic/stainsecadherin.html), [ER](https://www.pathologyoutlines.com/topic/stainser.html), [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html) (usually)+ Contains pseudopapillary architecture, which is rare in neuroendocrine tumors* [Mixed neuroendocrine nonneuroendocrine neoplasms (MiNEN)](https://www.pathologyoutlines.com/topic/pancreasmixed.html):\n    + Typically, neuroendocrine component is mixed with a ductal adenocarcinoma, occasionally with acinar cell carcinoma+ Each component must account for > 30% of the tumor* **Metastatic neuroendocrine tumors of other origin**:\n      + Negative for [islet 1](https://www.pathologyoutlines.com/topic/stainsislet1.html), **PAX6**, **PDX1**+ Positive for [TTF1](https://www.pathologyoutlines.com/topic/stainsttf1.html), [SATB2](https://www.pathologyoutlines.com/topic/stainssatb2.html), [CDX2](https://www.pathologyoutlines.com/topic/stainscdx2.html) ([Surg Oncol Clin N Am 2020;29:185](32151355))* [Neuroendocrine carcinoma (NEC)](https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html):\n        + High mitotic rate (> 20/2 mm2 or [Ki67](https://www.pathologyoutlines.com/topic/stainski67.html) > 20%)+ Large or small cell with corresponding high grade morphology* [Acinar cell carcinoma](https://www.pathologyoutlines.com/topic/pancreasacinar.html) ([Am J Surg Pathol 1992;16:815](1384374), [Cancer Cytopathol 2013;121:459](23408736)):\n          + [PAS](https://www.pathologyoutlines.com/topic/stainspas.html)+ diastase resistant granules sometimes detected+ Positive stains: [trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html), [chymotrypsin](https://www.pathologyoutlines.com/topic/stainsalpha1antichymo.html), **lipase**, [CK8/18](https://www.pathologyoutlines.com/topic/CK818.html)+ Occasionally positive for [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) or [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html)* [Pancreatoblastoma](https://www.pathologyoutlines.com/topic/pancreaspancreatoblastoma.html) ([Cancer Cytopathol 2013;121:459](23408736)):\n            + Solid and acinar patterns, squamoid nests are present+ [Trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html), [chymotrypsin](https://www.pathologyoutlines.com/topic/stainsalpha1antichymo.html), **lipase**, [BCL10](https://www.pathologyoutlines.com/topic/stainsbcl10.html), [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) and [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html) can be focally positive* [Glomus tumor](https://www.pathologyoutlines.com/topic/stomachglomus.html):\n              + Composed of 3 cell types: glomus, vasculature and smooth muscle cells+ Positive [SMA](https://www.pathologyoutlines.com/topic/stainsalphasmoothmuscleactin.html), negative [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html), [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html)"
  },
  {
    "id": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt-29",
    "source_document": "well-differentiated-neuroendocrine-tumor_42097_1750166976.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/pancreasWDNET.html#additionalreferences396304",
    "clean_content": "Additional references\n\n* [Lloyd: WHO Classification of Tumours of Endocrine Organs, 4th Edition, 2017](https://www.amazon.com/exec/obidos/ASIN/ 9283244931/pathologyoutl-20), [WHO Classification of Tumours Editorial Board: Digestive System Tumours, 5th Edition, 2019](https://www.amazon.com/exec/obidos/ASIN/9283244990/pathologyoutl-20)"
  }
]